Latest News

The zoldonrasib data build on the recent historical breakthrough with daraxonrasib in PDAC.

ASCO 2026 data reshapes lung cancer care, highlighting durable ALK control, new EGFR options, bispecific first-line gains, and SCLC progress.

Data link food deserts to metastatic breast cancer mutations and shorter survival, urging oncologists to screen for food insecurity.

Experts weigh leading IO/TKI combos for advanced RCC, comparing trials, toxicities, metastasis sites, and CNS strategy to personalize first-line care.

A randomized comparison of ATG, PTCy, and a combination helped characterize the similarities and differences of these regimens used as GVHD prophylaxis in stem cell transplant.

Triplet therapy ziftomenib plus venetoclax/azacitidine boosts MRD-negative remissions in relapsed NPM1-mutated AML, hinting at earlier use.

ASCO 2026 highlights, FDA moves, and AI mammography sharpen breast cancer care—ADCs, ctDNA, and de-escalation reshape treatment and screening debates.

FDA oncology Q2 2026 brings major breast, prostate and kidney cancer approvals, split ODAC votes, and RP1 melanoma setback heading into Q3.

During a live event, Syed Abbas Ali, MBBS, and participants discussed treatment selection for a patient who has not yet received BCMA-targeted therapy after a second relapse of multiple myeloma.

The clinicopathologic gene expression profile was granted the BDD status by the FDA for patients with T1b and T2a melanoma.

June 2026 FDA oncology updates bring major breast cancer shifts plus new prostate and kidney approvals, while melanoma and NET imaging decisions loom.

The T-cell immunotherapy Orca-T has gained FDA approval in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndromes (MDS).

During a live event, Zev Wainberg, MD, and participants discussed frontline immunotherapy selection in advanced HER2-negative gastrointestinal cancers.

Catherine Coombs, MD and oncologists weigh frontline CLL therapy choices, balancing BTK inhibitors vs fixed-duration venetoclax combinations as age, comorbidities, and new trial data guide decisions.

Phase 3 trial shows chemo-free epcoritamab plus lenalidomide cuts progression risk in relapsed DLBCL, with no new safety signals.

Q3 2026 FDA oncology verdicts loom for ADCs and targeted drugs in breast, melanoma, gastric, blood, and lung cancers.

Explore how GI and pancreatic NET sites shape symptoms and survival, plus NCCN-backed therapies from somatostatin analogs to PRRT and cabozantinib.

During a live event, Andrew Brunner, MD, and participants discussed escalating therapy in luspatercept-refractory LR-MDS.

During a live event, Matthew Rettig, MD, and participating oncologists discussed a case of a 74-year-old man with metastatic hormone-sensitive prostate cancer.

FDA issues CRL for Ga-68 edotreotide NET PET kit, citing third-party manufacturing; decentralized SSTR imaging promise remains pending.

After 2 prior CRLs, the FDA accepted a resubmitted BLA as a complete class 1 response with a goal date of August 2, 2026 for the oncolytic therapy for melanoma.

Genetic testing isn’t the finish line—learn how evolving risk models, dense breast guidance, and MCED screening may transform early cancer detection.

FDA clears BESREMi Pen, adding a simpler self-injection choice for adults with polycythemia vera on long-term ropeginterferon therapy.

TRIDENT shows early TTFields with chemoradiation doesn’t boost survival in newly diagnosed glioblastoma, but remains feasible with stable safety.

MammaPrint in the FLEX registry predicts which HR+/HER2– early breast cancers benefit from anthracyclines—guiding safer, personalized chemo.

Experts debate tivozanib’s durable responses and tolerability after immunotherapy in metastatic RCC, shaping smarter VEGFR-TKI sequencing.

Tentative approval was given for multiple dose levels of generic enzalutamide tablets for prostate cancer, including 120-mg and 160-mg doses.

Heather J. Landau, MD, discussed promising results of CAR T-cell therapy in light chain amyloidosis and the challenge of developing trials for this rare plasma cell disorder.

Myriad’s Precise MRD expands to breast, colorectal and renal cancers, using serial ctDNA tracking to spot residual disease and predict response.

During a live event, Gurbakhash Kaur, MD, and Donna Catamero, ANP-BC, OCN, CCRC, and participants discussed frontline treatment selection, duration of therapy, and the emerging role of MRD-guided decision-making in newly diagnosed multiple myeloma.

Ranjit Goudar, MD explains how community oncology practices are expanding hereditary cancer care through genetic testing, workflow redesign, and personalized prevention strategies.